MRI contrast agents, especially gadolinium-based ones, can improve diagnostic accuracy but also carry potential health risks. Updated clinical recommendations emphasize careful patient selection, dose ...

The FDA has started a review of a novel MRI contrast agent developed by Bayer that can reduce levels of gadolinium, a rare earth metal that can have damaging health and environmental consequences.

New results in animals highlight a major safety concern regarding a class of magnetic resonance imaging (MRI) contrast agents used in millions of patients each year. The study adds to concerns that ...

GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) ...

GE HealthCare doses first patient in phase 2/3 LUMINA trial for manganese-based MRI contrast agent, mangaciclanol: Chalfont St Giles,?UK Saturday, April 25, 2026, 12:00 Hrs [IST] ...

GE HealthCare Technologies (NasdaqGS:GEHC) has dosed the first patient in its global LUMINA Phase 2/3 trial of mangaciclanol, ...

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best NASDAQ stocks with the highest upside potential. On April 23 ...

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best medical device stocks to invest in right now. Piper Sandler cut the price target on GE HealthCare Technologies Inc.

On April 18, Andrew Slimmon, Managing Director & Senior Portfolio Manager at Morgan Stanley Investment Management, appeared ...

Bayer has reaffirmed its growth ambitions towards 2030, underpinned by a strengthened pharmaceutical portfolio, advanced ...